Amylyx Pharmaceuticals (AMLX) EBITDA Margin (2021 - 2024)
Historic EBITDA Margin for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to 155.0%.
- Amylyx Pharmaceuticals' EBITDA Margin fell 1565200.0% to 155.0% in Q4 2024 from the same period last year, while for Sep 2025 it was 599.87%, marking a year-over-year decrease of 4742800.0%. This contributed to the annual value of 275.44% for FY2024, which is 2844300.0% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its EBITDA Margin stood at 155.0% for Q4 2024, which was down 1565200.0% from 18187.74% recorded in Q3 2024.
- Amylyx Pharmaceuticals' EBITDA Margin's 5-year high stood at 18.63% during Q2 2023, with a 5-year trough of 18187.74% in Q3 2024.
- For the 4-year period, Amylyx Pharmaceuticals' EBITDA Margin averaged around 4009.91%, with its median value being 155.0% (2024).
- As far as peak fluctuations go, Amylyx Pharmaceuticals' EBITDA Margin soared by 100132600bps in 2023, and later plummeted by -182044700bps in 2024.
- Quarter analysis of 4 years shows Amylyx Pharmaceuticals' EBITDA Margin stood at 8041.4% in 2021, then surged by 98bps to 167.91% in 2022, then surged by 101bps to 1.53% in 2023, then crashed by -10247bps to 155.0% in 2024.
- Its EBITDA Margin stands at 155.0% for Q4 2024, versus 18187.74% for Q3 2024 and 7457.09% for Q2 2024.